Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma)
Lianyungang, China
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (3)
○ EMA GMP
○ MHRA GMP
Quick Facts: Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma)
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Lianyungang, China
- Modalities
- Small Molecule API, Biologics, Monoclonal Antibody, ADC, Oncology Drugs, Surgical Medicines
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma)
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesSmall Molecule API, Biologics, Monoclonal Antibody, ADC, Oncology Drugs, Surgical Medicines
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (6 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press3 articles
Broad modality coverage (6 modalities)
Recent News 3 articles
MSD enters agreement with Hengrui Pharma for Lp(a) inhibitor - Pharmaceutical Technology
Hengrui Pharma Launches New Company to Make Medicine Accessible - BioSpace
Merck Licenses Lp(a) Inhibitor from Hengrui Pharma - Contract Pharma
Frequently Asked Questions About Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma)
What is Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma)'s CDMO Signal Score?
Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for a manufacturing program?
Use the free AI matchmaker to compare Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Altruist Biologics
Suzhou, China
Biologics, mAb, Bispecific/Multispecific Antibodies, Fusion Proteins, Recombinant Proteins, ADC, Cell Therapy, Gene Therapy
AsymBio
Shanghai, China
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, ADC, Bioconjugates (NDC, RDC, AOC, PDC, BsADC), Plasmid DNA, mRNA, Fill-Finish
Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.)
Hangzhou, China
Monoclonal Antibody, Recombinant Protein, Bispecific Antibody, Fusion Protein, ADC, XDC (ADC, RDC, Bioconjugates), Cell Line Development (CHO)
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 83.7
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
Signal Score: 83.6
Biologics, ADC